Monkeys developed tooth and jaw abscesses and two died of protozoal infections.
Human subjects developed cervical, ovarian, pancreatic, gastric and thyroid cancers and breast cancer "was the most common adverse event that led to discontinuation" in trials. Adverse effect?
Ten people were hospitalized with the skin infection cellulitis during trials and one died.
But the FDA approved Amgen's Prolia (denosumab) this month to prevent fractures in women with osteoporosis, two months earlier than expected. And with Amgen consultants sitting unabashedly on the Advisory Committee for Reproductive Health Drugs.
(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).